-
1
-
-
34249068954
-
An HIV-1 vaccine-evolving concepts
-
doi:10.1056/NEJMra066267. PubMed: 17507706
-
Johnston MI, Fauci AS (2007) An HIV-1 vaccine-evolving concepts. N Engl J Med 356: 2073-2081. doi:10.1056/NEJMra066267. PubMed: 17507706.
-
(2007)
N Engl J Med
, vol.356
, pp. 2073-2081
-
-
Johnston, M.I.1
Fauci, A.S.2
-
2
-
-
33646172660
-
HIV vaccines
-
doi:10.1146/annurev.immunol.24.021605.090605. PubMed: 16551249
-
McMichael AJ (2006) HIV vaccines. Annu Rev Immunol 24: 227-255. doi:10.1146/annurev.immunol.24.021605.090605. PubMed: 16551249.
-
(2006)
Annu Rev Immunol
, vol.24
, pp. 227-255
-
-
McMichael, A.J.1
-
3
-
-
56649105122
-
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
-
doi:10.1016/S0140-6736(08)61591-3. PubMed: 19012954
-
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893. doi:10.1016/S0140-6736(08)61591-3. PubMed: 19012954.
-
(2008)
Lancet
, vol.372
, pp. 1881-1893
-
-
Buchbinder, S.P.1
Mehrotra, D.V.2
Duerr, A.3
Fitzgerald, D.W.4
Mogg, R.5
-
4
-
-
13944254982
-
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
-
doi:10.1086/428404. PubMed: 15688278
-
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665. doi:10.1086/428404. PubMed: 15688278.
-
(2005)
J Infect Dis
, vol.191
, pp. 654-665
-
-
Flynn, N.M.1
Forthal, D.N.2
Harro, C.D.3
Judson, F.N.4
Mayer, K.H.5
-
5
-
-
73349094086
-
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
-
doi:10.1056/NEJMoa0908492. PubMed: 19843557
-
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
-
(2009)
N Engl J Med
, vol.361
, pp. 2209-2220
-
-
Rerks-Ngarm, S.1
Pitisuttithum, P.2
Nitayaphan, S.3
Kaewkungwal, J.4
Chiu, J.5
-
7
-
-
84891585599
-
-
National Institute of Allergy and Infectious Diseases National Institutes of Health Updated April 25th
-
National Institute of Allergy and Infectious Diseases National Institutes of Health (2013) QUESTIONS AND ANSWERS : The HVTN 505 HIV Vaccine Regimen Study. Updated April 25th.
-
(2013)
QUESTIONS and ANSWERS: The HVTN 505 HIV Vaccine Regimen Study
-
-
-
8
-
-
84875579579
-
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E
-
doi:10.1093/infdis/jis478. PubMed: 22837492
-
Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C et al. (2013) Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis 207: 1195-1205. doi:10.1093/infdis/ jis478. PubMed: 22837492.
-
(2013)
J Infect Dis
, vol.207
, pp. 1195-1205
-
-
Rerks-Ngarm, S.1
Paris, R.M.2
Chunsutthiwat, S.3
Premsri, N.4
Namwat, C.5
-
9
-
-
73349084980
-
HIV vaccine trial results - An opening for further research
-
doi:10.1056/NEJMe0909972. PubMed: 19843556
-
Dolin R (2009) HIV vaccine trial results - an opening for further research. N Engl J Med 361: 2279-2280. doi:10.1056/NEJMe0909972. PubMed: 19843556.
-
(2009)
N Engl J Med
, vol.361
, pp. 2279-2280
-
-
Dolin, R.1
-
10
-
-
84861173075
-
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope
-
doi:10.4049/jimmunol.1102756. PubMed: 22529301
-
de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176. doi:10.4049/jimmunol.1102756. PubMed: 22529301.
-
(2012)
J Immunol
, vol.188
, pp. 5166-5176
-
-
De Souza, M.S.1
Ratto-Kim, S.2
Chuenarom, W.3
Schuetz, A.4
Chantakulkij, S.5
-
11
-
-
84859393693
-
Immune-correlates analysis of an HIV-1 vaccine efficacy trial
-
doi:10.1056/NEJMoa1113425. PubMed: 22475592
-
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286. doi:10.1056/NEJMoa1113425. PubMed: 22475592.
-
(2012)
N Engl J Med
, vol.366
, pp. 1275-1286
-
-
Haynes, B.F.1
Gilbert, P.B.2
McElrath, M.J.3
Zolla-Pazner, S.4
Tomaras, G.D.5
-
12
-
-
77954357410
-
Correlates of protection induced by vaccination
-
doi:10.1128/CVI.00131-10. PubMed: 20463105
-
Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065. doi:10.1128/CVI.00131-10. PubMed: 20463105.
-
(2010)
Clin Vaccine Immunol
, vol.17
, pp. 1055-1065
-
-
Plotkin, S.A.1
-
13
-
-
2942534479
-
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
-
doi:10.1086/420833. PubMed: 15181562
-
Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T et al. (2004) Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189: 2167-2173. doi:10.1086/420833. PubMed: 15181562.
-
(2004)
J Infect Dis
, vol.189
, pp. 2167-2173
-
-
Ferrantelli, F.1
Rasmussen, R.A.2
Buckley, K.A.3
Li, P.L.4
Wang, T.5
-
14
-
-
67249131966
-
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
-
PubMed: 19436712
-
Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433. PubMed: 19436712.
-
(2009)
PLoS Pathog
, vol.5
-
-
Hessell, A.J.1
Rakasz, E.G.2
Poignard, P.3
Hangartner, L.4
Landucci, G.5
-
15
-
-
0032947286
-
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
-
PubMed: 10196297
-
Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018. PubMed: 10196297.
-
(1999)
J Virol
, vol.73
, pp. 4009-4018
-
-
Mascola, J.R.1
Lewis, M.G.2
Stiegler, G.3
Harris, D.4
VanCott, T.C.5
-
16
-
-
0034864776
-
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
-
doi: 10.1128/JVI.75.17.8340-8347.2001. PubMed: 11483779
-
Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347. doi: 10.1128/JVI.75.17.8340- 8347.2001. PubMed: 11483779.
-
(2001)
J Virol
, vol.75
, pp. 8340-8347
-
-
Parren, P.W.1
Marx, P.A.2
Hessell, A.J.3
Luckay, A.4
Harouse, J.5
-
17
-
-
84855466746
-
Antibody-based protection against HIV infection by vectored immunoprophylaxis
-
PubMed: 22139420
-
Balazs AB, Chen J, Hong CM, Rao DS, Yang L et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84. PubMed: 22139420.
-
(2012)
Nature
, vol.481
, pp. 81-84
-
-
Balazs, A.B.1
Chen, J.2
Hong, C.M.3
Rao, D.S.4
Yang, L.5
-
18
-
-
84866250119
-
Gene therapy as a vaccine for HIV-1
-
doi:10.1517/14712598.2012.707177. PubMed: 22803517
-
Berkhout B, Sanders RW (2012) Gene therapy as a vaccine for HIV-1. Expert Opin Biol Ther 12: 1315-1321. doi:10.1517/14712598.2012.707177. PubMed: 22803517.
-
(2012)
Expert Opin Biol Ther
, vol.12
, pp. 1315-1321
-
-
Berkhout, B.1
Sanders, R.W.2
-
19
-
-
77954722964
-
Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
-
doi:10.1086/654816. PubMed: 20608874
-
Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M et al. (2010) Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 202: 595-605. doi:10.1086/654816. PubMed: 20608874.
-
(2010)
J Infect Dis
, vol.202
, pp. 595-605
-
-
Gilbert, P.1
Wang, M.2
Wrin, T.3
Petropoulos, C.4
Gurwith, M.5
-
20
-
-
24644479045
-
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine
-
doi:10.1086/432734. PubMed: 16107949
-
Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V et al. (2005) HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 192: 974-983. doi:10.1086/432734. PubMed: 16107949.
-
(2005)
J Infect Dis
, vol.192
, pp. 974-983
-
-
Gilbert, P.B.1
Ackers, M.L.2
Berman, P.W.3
Francis, D.P.4
Popovic, V.5
-
21
-
-
13944250922
-
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
-
doi:10.1086/428405. PubMed: 15688279
-
Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677. doi:10.1086/428405. PubMed: 15688279.
-
(2005)
J Infect Dis
, vol.191
, pp. 666-677
-
-
Gilbert, P.B.1
Peterson, M.L.2
Follmann, D.3
Hudgens, M.G.4
Francis, D.P.5
-
22
-
-
33845433434
-
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
-
doi:10.1086/508748. PubMed: 17109337
-
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. doi:10.1086/508748. PubMed: 17109337.
-
(2006)
J Infect Dis
, vol.194
, pp. 1661-1671
-
-
Pitisuttithum, P.1
Gilbert, P.2
Gurwith, M.3
Heyward, W.4
Martin, M.5
-
23
-
-
84862904805
-
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
-
doi:10.1093/infdis/jis342. PubMed: 22561365
-
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J et al. (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206: 258-266. doi:10.1093/infdis/jis342. PubMed: 22561365.
-
(2012)
J Infect Dis
, vol.206
, pp. 258-266
-
-
Duerr, A.1
Huang, Y.2
Buchbinder, S.3
Coombs, R.W.4
Sanchez, J.5
-
24
-
-
84875771414
-
Antigenicity and Immunogenicity of Transmitted/Founder, Consensus and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1
-
Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N et al. (2013) Antigenicity and Immunogenicity of Transmitted/Founder, Consensus and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. J Virol.
-
(2013)
J Virol
-
-
Liao, H.X.1
Tsao, C.Y.2
Alam, S.M.3
Muldoon, M.4
Vandergrift, N.5
-
25
-
-
84874277923
-
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study
-
doi:10.1016/S1473-3099(12)70345-6. PubMed: 23369412
-
Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J et al. (2013) Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13: 238-250. doi:10.1016/S1473-3099(12)70345-6. PubMed: 23369412.
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 238-250
-
-
Gurwith, M.1
Lock, M.2
Taylor, E.M.3
Ishioka, G.4
Alexander, J.5
-
26
-
-
84878528694
-
Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design
-
doi:10.1128/JVI.03577-12. PubMed: 23616655
-
Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF et al. (2013) Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. J Virol 87: 7218-7233. doi:10.1128/JVI.03577-12. PubMed: 23616655.
-
(2013)
J Virol
, vol.87
, pp. 7218-7233
-
-
Ping, L.H.1
Joseph, S.B.2
Anderson, J.A.3
Abrahams, M.R.4
Salazar-Gonzalez, J.F.5
-
27
-
-
77649145875
-
Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates
-
doi:10.1186/1743-422X-7-39. PubMed: 20163742
-
Takahashi MN, Rolling JA, Owen KE (2010) Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates. Virol J 7: 39. doi:10.1186/1743-422X-7-39. PubMed: 20163742.
-
(2010)
Virol J
, vol.7
, pp. 39
-
-
Takahashi, M.N.1
Rolling, J.A.2
Owen, K.E.3
-
29
-
-
84857177060
-
Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin
-
doi:10.1371/journal.pone.0031177. PubMed: 22363572
-
Alexander J, Ward S, Mendy J, Manayani DJ, Farness P et al. (2012) Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLOS ONE 7: e31177. doi:10.1371/journal.pone.0031177. PubMed: 22363572.
-
(2012)
PLOS ONE
, vol.7
-
-
Alexander, J.1
Ward, S.2
Mendy, J.3
Manayani, D.J.4
Farness, P.5
-
30
-
-
16944365650
-
Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles
-
doi:10.1089/hum.1997.8.4-453. PubMed: 9054520
-
Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT et al. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8: 453-465. doi:10.1089/hum.1997.8.4-453. PubMed: 9054520.
-
(1997)
Hum Gene Ther
, vol.8
, pp. 453-465
-
-
Shabram, P.W.1
Giroux, D.D.2
Goudreau, A.M.3
Gregory, R.J.4
Horn, M.T.5
-
31
-
-
70350134276
-
Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
-
doi:10.1016/j.virol.2009.07.041. PubMed: 19744690
-
Gao F, Scearce RM, Alam SM, Hora B, Xia S et al. (2009) Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 394: 91-98. doi:10.1016/j.virol.2009.07.041. PubMed: 19744690.
-
(2009)
Virology
, vol.394
, pp. 91-98
-
-
Gao, F.1
Scearce, R.M.2
Alam, S.M.3
Hora, B.4
Xia, S.5
-
32
-
-
0032210842
-
Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
-
doi:10.1016/S0264-410X(98)00182-0. PubMed: 9795384
-
Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z (1998) Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16: 1803-1811. doi:10.1016/S0264-410X(98)00182-0. PubMed: 9795384.
-
(1998)
Vaccine
, vol.16
, pp. 1803-1811
-
-
Pinter, A.1
Honnen, W.J.2
Kayman, S.C.3
Trochev, O.4
Wu, Z.5
-
33
-
-
84873051328
-
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
-
doi:10.1128/JVI.00718-12. PubMed: 23175357
-
Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY et al. (2013) Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87: 1554-1568. doi:10.1128/JVI.00718-12. PubMed: 23175357.
-
(2013)
J Virol
, vol.87
, pp. 1554-1568
-
-
Alam, S.M.1
Liao, H.X.2
Tomaras, G.D.3
Bonsignori, M.4
Tsao, C.Y.5
-
34
-
-
84891588664
-
Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes with V1/V2
-
doi:10.1186/1742-4690-9-S2-O31
-
Liao L, Bonsignori M, Hwang KK, Moody MA, Park R et al. (2012) Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes with V1/V2. Retrovirology 9(Suppl 2): O31. doi:10.1186/1742-4690-9-S2-O31.
-
(2012)
Retrovirology
, vol.9
, Issue.SUPPL. 2
-
-
Liao, L.1
Bonsignori, M.2
Hwang, K.K.3
Moody, M.A.4
Park, R.5
-
35
-
-
84863932778
-
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
-
doi:10.1093/infdis/jis367. PubMed: 22634875
-
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. doi:10.1093/infdis/jis367. PubMed: 22634875.
-
(2012)
J Infect Dis
, vol.206
, pp. 431-441
-
-
Montefiori, D.C.1
Karnasuta, C.2
Huang, Y.3
Ahmed, H.4
Gilbert, P.5
-
36
-
-
73949127978
-
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
-
doi:10.1128/JVI.02108-09. PubMed: 19939925
-
Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452. doi:10.1128/JVI.02108-09. PubMed: 19939925.
-
(2010)
J Virol
, vol.84
, pp. 1439-1452
-
-
Seaman, M.S.1
Janes, H.2
Hawkins, N.3
Grandpre, L.E.4
Devoy, C.5
-
37
-
-
83455254775
-
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
-
doi:10.1038/nature10696. PubMed: 22113616
-
McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343. doi:10.1038/nature10696. PubMed: 22113616.
-
(2011)
Nature
, vol.480
, pp. 336-343
-
-
McLellan, J.S.1
Pancera, M.2
Carrico, C.3
Gorman, J.4
Julien, J.P.5
-
38
-
-
80051737642
-
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation
-
doi:10.1016/j.jmb.2011.04.042. PubMed: 21762802
-
Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582-608. doi:10.1016/j.jmb.2011.04.042. PubMed: 21762802.
-
(2011)
J Mol Biol
, vol.410
, pp. 582-608
-
-
Checkley, M.A.1
Luttge, B.G.2
Freed, E.O.3
-
39
-
-
0022458750
-
Infectious mutants of HTLV-III with changes in the 3′ region and markedly reduced cytopathic effects
-
doi: 10.1126/science.3014663. PubMed: 3014663
-
Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME et al. (1986) Infectious mutants of HTLV-III with changes in the 3′ region and markedly reduced cytopathic effects. Science 233: 655-659. doi: 10.1126/science.3014663. PubMed: 3014663.
-
(1986)
Science
, vol.233
, pp. 655-659
-
-
Fisher, A.G.1
Ratner, L.2
Mitsuya, H.3
Marselle, L.M.4
Harper, M.E.5
-
40
-
-
0024375181
-
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity
-
doi:10.1089/aid.1989.5.441. PubMed: 2788444
-
Lee SJ, Hu W, Fisher AG, Looney DJ, Kao VF et al. (1989) Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses 5: 441-449. doi:10.1089/aid.1989.5.441. PubMed: 2788444.
-
(1989)
AIDS Res Hum Retroviruses
, vol.5
, pp. 441-449
-
-
Lee, S.J.1
Hu, W.2
Fisher, A.G.3
Looney, D.J.4
Kao, V.F.5
-
41
-
-
84871950126
-
The tale of the long tail: The cytoplasmic domain of HIV-1 gp41
-
doi:10.1128/JVI.02053-12. PubMed: 23077317
-
Postler TS, Desrosiers RC (2013) The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol 87: 2-15. doi:10.1128/JVI.02053-12. PubMed: 23077317.
-
(2013)
J Virol
, vol.87
, pp. 2-15
-
-
Postler, T.S.1
Desrosiers, R.C.2
-
42
-
-
67650444362
-
Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity
-
doi:10.1128/JVI.00374-09. PubMed: 19420074
-
Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M et al. (2009) Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J Virol 83: 7166-7175. doi:10.1128/JVI.00374-09. PubMed: 19420074.
-
(2009)
J Virol
, vol.83
, pp. 7166-7175
-
-
Wang, L.1
Cheng, C.2
Ko, S.Y.3
Kong, W.P.4
Kanekiyo, M.5
-
43
-
-
84868589536
-
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
-
doi:10.1089/aid.2012.0103. PubMed: 23035746
-
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S et al. (2012) The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 28: 1444-1457. doi:10.1089/aid.2012.0103. PubMed: 23035746.
-
(2012)
AIDS Res Hum Retroviruses
, vol.28
, pp. 1444-1457
-
-
Karasavvas, N.1
Billings, E.2
Rao, M.3
Williams, C.4
Zolla-Pazner, S.5
-
44
-
-
84867653590
-
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
-
doi:10.1038/nature11519. PubMed: 22960785
-
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420. doi:10.1038/nature11519. PubMed: 22960785.
-
(2012)
Nature
, vol.490
, pp. 417-420
-
-
Rolland, M.1
Edlefsen, P.T.2
Larsen, B.B.3
Tovanabutra, S.4
Sanders-Buell, E.5
-
45
-
-
2342644898
-
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
-
doi:10.1128/JVI.78.10.5205-5215.2004. PubMed: 15113902
-
Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215. doi:10.1128/JVI.78.10.5205-5215. 2004. PubMed: 15113902.
-
(2004)
J Virol
, vol.78
, pp. 5205-5215
-
-
Pinter, A.1
Honnen, W.J.2
He, Y.3
Gorny, M.K.4
Zolla-Pazner, S.5
-
46
-
-
33748925430
-
Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity
-
doi:10.1128/JVI.00141-06. PubMed: 16973562
-
Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598. doi:10.1128/JVI.00141-06. PubMed: 16973562.
-
(2006)
J Virol
, vol.80
, pp. 9586-9598
-
-
Sagar, M.1
Wu, X.2
Lee, S.3
Overbaugh, J.4
-
47
-
-
73949112038
-
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1
-
doi:10.1073/pnas.0911796106. PubMed: 19933330
-
Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R et al. (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 106: 20877-20882. doi:10.1073/pnas.0911796106. PubMed: 19933330.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 20877-20882
-
-
Cicala, C.1
Martinelli, E.2
McNally, J.P.3
Goode, D.J.4
Gopaul, R.5
-
48
-
-
79952232940
-
The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission
-
Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K et al. (2011) The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLOS Pathog 7: e1001301.
-
(2011)
PLOS Pathog
, vol.7
-
-
Nawaz, F.1
Cicala, C.2
Van Ryk, D.3
Block, K.E.4
Jelicic, K.5
-
49
-
-
84862828547
-
Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
-
doi:10.1016/j.virol.2012.02.003. PubMed: 22402248
-
Gorny MK, Pan R, Williams C, Wang XH, Volsky B et al. (2012) Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 427: 198-207. doi:10.1016/j.virol.2012.02. 003. PubMed: 22402248.
-
(2012)
Virology
, vol.427
, pp. 198-207
-
-
Gorny, M.K.1
Pan, R.2
Williams, C.3
Wang, X.H.4
Volsky, B.5
-
50
-
-
80053132436
-
Broad neutralization coverage of HIV by multiple highly potent antibodies
-
doi:10.1038/nature10373. PubMed: 21849977
-
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470. doi:10.1038/nature10373. PubMed: 21849977.
-
(2011)
Nature
, vol.477
, pp. 466-470
-
-
Walker, L.M.1
Huber, M.2
Doores, K.J.3
Falkowska, E.4
Pejchal, R.5
-
51
-
-
77951882041
-
Toward an antibody-based HIV-1 vaccine
-
doi:10.1146/annurev.med.60.042507.164323. PubMed: 19824826
-
Hoxie JA (2010) Toward an antibody-based HIV-1 vaccine. Annu Rev Med 61: 135-152. doi:10.1146/annurev.med.60.042507.164323. PubMed: 19824826.
-
(2010)
Annu Rev Med
, vol.61
, pp. 135-152
-
-
Hoxie, J.A.1
-
52
-
-
77952311370
-
The role of antibodies in HIV vaccines
-
doi:10.1146/annurev-immunol-030409-101256. PubMed: 20192810
-
Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444. doi:10.1146/annurev-immunol-030409-101256. PubMed: 20192810.
-
(2010)
Annu Rev Immunol
, vol.28
, pp. 413-444
-
-
Mascola, J.R.1
Montefiori, D.C.2
-
53
-
-
84857306337
-
Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site
-
doi:10.1074/jbc.M111.317776. PubMed: 22167180
-
Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD et al. (2012) Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem 287: 5673-5686. doi:10.1074/jbc.M111.317776. PubMed: 22167180.
-
(2012)
J Biol Chem
, vol.287
, pp. 5673-5686
-
-
Feng, Y.1
McKee, K.2
Tran, K.3
O'Dell, S.4
Schmidt, S.D.5
-
54
-
-
80052938385
-
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
-
doi:10.1128/JVI.05045-11. PubMed: 21795340
-
Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998-10009. doi:10.1128/JVI.05045-11. PubMed: 21795340.
-
(2011)
J Virol
, vol.85
, pp. 9998-10009
-
-
Bonsignori, M.1
Hwang, K.K.2
Chen, X.3
Tsao, C.Y.4
Morris, L.5
-
55
-
-
77649318846
-
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
-
doi:10.1371/journal.pone.0008805. PubMed: 20098712
-
Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLOS ONE 5: e8805. doi:10.1371/journal.pone.0008805. PubMed: 20098712.
-
(2010)
PLOS ONE
, vol.5
-
-
Corti, D.1
Langedijk, J.P.2
Hinz, A.3
Seaman, M.S.4
Vanzetta, F.5
-
56
-
-
33646146379
-
GP120: Target for neutralizing HIV-1 antibodies
-
doi:10.1146/annurev.immunol.24.021605.090557. PubMed: 16551265
-
Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769. doi:10.1146/annurev.immunol.24.021605. 090557. PubMed: 16551265.
-
(2006)
Annu Rev Immunol
, vol.24
, pp. 739-769
-
-
Pantophlet, R.1
Burton, D.R.2
-
57
-
-
80052925616
-
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
-
doi:10.1126/science.1207227. PubMed: 21764753
-
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637. doi:10.1126/science.1207227. PubMed: 21764753.
-
(2011)
Science
, vol.333
, pp. 1633-1637
-
-
Scheid, J.F.1
Mouquet, H.2
Ueberheide, B.3
Diskin, R.4
Klein, F.5
-
58
-
-
0032546844
-
The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
-
doi:10.1126/science.280.5371.1884. PubMed: 9632381
-
Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888. doi:10.1126/science.280.5371. 1884. PubMed: 9632381.
-
(1998)
Science
, vol.280
, pp. 1884-1888
-
-
Wyatt, R.1
Sodroski, J.2
-
59
-
-
70449701456
-
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens
-
doi:10.1016/j.bbrc.2009.09.029. PubMed: 19748484
-
Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P et al. (2009) Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390: 404-409. doi:10.1016/j.bbrc.2009.09.029. PubMed: 19748484.
-
(2009)
Biochem Biophys Res Commun
, vol.390
, pp. 404-409
-
-
Xiao, X.1
Chen, W.2
Feng, Y.3
Zhu, Z.4
Prabakaran, P.5
-
60
-
-
84867902637
-
HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design
-
doi:10.1016/j.tim.2012.08.011. PubMed: 22981828
-
Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD et al. (2012) HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 20: 532-539. doi:10.1016/j.tim.2012.08.011. PubMed: 22981828.
-
(2012)
Trends Microbiol
, vol.20
, pp. 532-539
-
-
Bonsignori, M.1
Alam, S.M.2
Liao, H.X.3
Verkoczy, L.4
Tomaras, G.D.5
-
61
-
-
84860759632
-
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
-
doi:10.1038/nbt.2197. PubMed: 22565972
-
Haynes BF, Kelsoe G, Harrison SC, Kepler TB (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30: 423-433. doi:10.1038/nbt.2197. PubMed: 22565972.
-
(2012)
Nat Biotechnol
, vol.30
, pp. 423-433
-
-
Haynes, B.F.1
Kelsoe, G.2
Harrison, S.C.3
Kepler, T.B.4
-
62
-
-
82955201800
-
Prospects for an HIV vaccine: Leading B cells down the right path
-
doi:10.1038/nsmb.2194. PubMed: 22139037
-
Moir S, Malaspina A, Fauci AS (2011) Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol 18: 1317-1321. doi:10.1038/nsmb.2194. PubMed: 22139037.
-
(2011)
Nat Struct Mol Biol
, vol.18
, pp. 1317-1321
-
-
Moir, S.1
Malaspina, A.2
Fauci, A.S.3
-
63
-
-
33947590277
-
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
-
doi:10.1016/j.virol.2006.10.032. PubMed: 17126869
-
Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP et al. (2007) A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329-340. doi:10.1016/j.virol.2006.10.032. PubMed: 17126869.
-
(2007)
Virology
, vol.360
, pp. 329-340
-
-
Beddows, S.1
Franti, M.2
Dey, A.K.3
Kirschner, M.4
Iyer, S.P.5
-
64
-
-
79551556431
-
Heterologous epitope-scaffold prime:Boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant
-
doi:10.1371/journal.pone.0016074. PubMed: 21297864
-
Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR et al. (2011) Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLOS ONE 6: e16074. doi:10.1371/journal.pone.0016074. PubMed: 21297864.
-
(2011)
PLOS ONE
, vol.6
-
-
Guenaga, J.1
Dosenovic, P.2
Ofek, G.3
Baker, D.4
Schief, W.R.5
-
65
-
-
84861324362
-
HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes
-
doi:10.1128/JVI.06938-11. PubMed: 22301141
-
Tong T, Crooks ET, Osawa K, Binley JM (2012) HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 86: 3574-3587. doi:10.1128/JVI.06938-11. PubMed: 22301141.
-
(2012)
J Virol
, vol.86
, pp. 3574-3587
-
-
Tong, T.1
Crooks, E.T.2
Osawa, K.3
Binley, J.M.4
-
66
-
-
80053952246
-
Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120
-
doi:10.1128/JVI.05086-11
-
Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nadas A et al. (2011) Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120. DNA - J Virol 85: 9887-9898. doi:10.1128/JVI.05086-11.
-
(2011)
DNA - J Virol
, vol.85
, pp. 9887-9898
-
-
Zolla-Pazner, S.1
Kong, X.P.2
Jiang, X.3
Cardozo, T.4
Nadas, A.5
-
67
-
-
0031769029
-
Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: Results of a retrospective nationwide seroprevalence survey
-
doi:10.1086/314498. PubMed: 9815232
-
Ludwig SL, Brundage JF, Kelley PW, Nang R, Towle C et al. (1998) Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis 178: 1776-1778. doi:10.1086/314498. PubMed: 9815232.
-
(1998)
J Infect Dis
, vol.178
, pp. 1776-1778
-
-
Ludwig, S.L.1
Brundage, J.F.2
Kelley, P.W.3
Nang, R.4
Towle, C.5
|